296 related articles for article (PubMed ID: 14617792)
1. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Bonavida B
Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
4. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
Alas S; Ng CP; Bonavida B
Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
[TBL] [Abstract][Full Text] [Related]
5. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
8. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
9. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
10. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B
J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
14. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
Skvortsova I; Popper BA; Skvortsov S; Saurer M; Auer T; Moser R; Kamleitner H; Zwierzina H; Lukas P
J Radiat Res; 2005 Jun; 46(2):241-8. PubMed ID: 15988143
[TBL] [Abstract][Full Text] [Related]
16. PSAP induces a unique Apaf-1 and Smac-dependent mitochondrial apoptotic pathway independent of Bcl-2 family proteins.
Li T; Zeng L; Gao W; Cui MZ; Fu X; Xu X
Biochim Biophys Acta; 2013 Mar; 1832(3):453-74. PubMed ID: 23207240
[TBL] [Abstract][Full Text] [Related]
17. CD20-induced B cell death can bypass mitochondria and caspase activation.
van der Kolk LE; Evers LM; Omene C; Lens SM; Lederman S; van Lier RA; van Oers MH; Eldering E
Leukemia; 2002 Sep; 16(9):1735-44. PubMed ID: 12200688
[TBL] [Abstract][Full Text] [Related]
18. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
19. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Shan D; Ledbetter JA; Press OW
Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
[TBL] [Abstract][Full Text] [Related]
20. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
